The article discusses the growing interest and skepticism surrounding the use of artificial intelligence in drug discovery and development. Proponents highlight tools like AlphaFold, which predict protein structures, as revolutionary. However, critics argue that AI has not yet overcome the high failure rates in drug trials. The authors balance these views, suggesting AI is a valuable tool when applied correctly, capable of addressing fundamental issues in drug development and potentially reducing time and costs but caution that it isn't a panacea.
AI's potential to accelerate drug discovery needs a reality check, as AI-generated drugs have yet to demonstrate an ability to address the 90% failure rate of new drugs in clinical trials.
AI in drug development is not yet a game-changer, nor is it complete nonsense. Rather, we see it as a tool that could help address the root causes of drug failure.
Collection
[
|
...
]